ES2178943B1 - Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. - Google Patents

Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.

Info

Publication number
ES2178943B1
ES2178943B1 ES200002868A ES200002868A ES2178943B1 ES 2178943 B1 ES2178943 B1 ES 2178943B1 ES 200002868 A ES200002868 A ES 200002868A ES 200002868 A ES200002868 A ES 200002868A ES 2178943 B1 ES2178943 B1 ES 2178943B1
Authority
ES
Spain
Prior art keywords
treatment
pulmonary disease
chronic obstructive
obstructive pulmonary
organic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200002868A
Other languages
English (en)
Other versions
ES2178943A1 (es
Inventor
Barbara Haeberlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2178943(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of ES2178943A1 publication Critical patent/ES2178943A1/es
Application granted granted Critical
Publication of ES2178943B1 publication Critical patent/ES2178943B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de compuestos orgánicos en el tratamiento de enfermedad pulmonar obstructiva crónica, en particular uso de un polvo seco que comprende (A) formoterol o una sal o solvato del mismo farmacéuticamente aceptable, o un solvato de dicha sal, y (B) un diluyente o vehículo en partículas, farmacéuticamente aceptable, en una cantidad de 400 {mi}g a 5.OOO {mi}g por {mi}g de (A), en la preparación de un medicamento inhalable para el tratamiento de la enfermedad pulmonar obstructiva crónica.
ES200002868A 1999-11-30 2000-11-30 Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. Expired - Fee Related ES2178943B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9928311.1A GB9928311D0 (en) 1999-11-30 1999-11-30 Organic compounds

Publications (2)

Publication Number Publication Date
ES2178943A1 ES2178943A1 (es) 2003-01-01
ES2178943B1 true ES2178943B1 (es) 2004-03-16

Family

ID=10865451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200002868A Expired - Fee Related ES2178943B1 (es) 1999-11-30 2000-11-30 Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.

Country Status (24)

Country Link
US (3) US6887459B1 (es)
EP (3) EP3050558A1 (es)
JP (3) JP2003515551A (es)
KR (1) KR100771281B1 (es)
CN (1) CN1399540A (es)
AU (1) AU769765B2 (es)
BR (1) BR0015908A (es)
CA (1) CA2389349C (es)
CZ (1) CZ20021850A3 (es)
ES (1) ES2178943B1 (es)
FR (1) FR2801506B1 (es)
GB (1) GB9928311D0 (es)
HU (1) HUP0203728A3 (es)
IL (2) IL149362A0 (es)
IT (1) ITMI20002556A1 (es)
MX (1) MXPA02005384A (es)
NO (1) NO20021963D0 (es)
NZ (1) NZ518873A (es)
PL (1) PL354974A1 (es)
RU (1) RU2327452C2 (es)
SK (1) SK7432002A3 (es)
TW (1) TWI278324B (es)
WO (1) WO2001039745A2 (es)
ZA (1) ZA200204147B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
JP2006516531A (ja) * 2002-08-21 2006-07-06 ノートン　ヘルスケアー　リミテッド 吸入組成物
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
NZ538965A (en) 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
GB0616299D0 (en) * 2006-08-16 2006-09-27 Cambridge Consultants Drug Capsules for dry power inhalers
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP2124915A2 (en) 2007-02-19 2009-12-02 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
WO2015065221A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
GB8911259D0 (en) * 1989-05-17 1989-07-05 Fisons Plc Inhalation medicament
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
ES2099428T3 (es) * 1992-03-10 1997-05-16 Fisons Plc Composiciones farmaceuticas para inhalacion.
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
ES2216418T3 (es) 1995-12-07 2004-10-16 Jago Research Ag Boquilla para un inhalador para la administracion de varias dosis de un polvo seco farmacologico.
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
AU738192B2 (en) 1997-09-19 2001-09-13 Neuren Pharmaceuticals Limited Neuronal rescue agent
GB9805102D0 (en) 1998-03-10 1998-05-06 Ciba Geigy Ag Device
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2001039745A3 (en) 2001-12-20
BR0015908A (pt) 2002-08-06
ES2178943A1 (es) 2003-01-01
IL149362A (en) 2015-06-30
KR100771281B1 (ko) 2007-10-29
RU2002116251A (ru) 2004-01-20
EP2011484A3 (en) 2009-01-14
US20050136010A1 (en) 2005-06-23
NO20021963L (no) 2002-04-25
KR20020058050A (ko) 2002-07-12
CZ20021850A3 (cs) 2002-08-14
CN1399540A (zh) 2003-02-26
EP1233757A2 (en) 2002-08-28
CA2389349C (en) 2009-10-20
US20070196286A1 (en) 2007-08-23
GB9928311D0 (en) 2000-01-26
AU769765B2 (en) 2004-02-05
MXPA02005384A (es) 2002-11-29
FR2801506A1 (fr) 2001-06-01
TWI278324B (en) 2007-04-11
PL354974A1 (en) 2004-03-22
RU2327452C2 (ru) 2008-06-27
JP2013075909A (ja) 2013-04-25
JP2015108020A (ja) 2015-06-11
HUP0203728A3 (en) 2003-12-29
EP3050558A1 (en) 2016-08-03
US6887459B1 (en) 2005-05-03
AU2837401A (en) 2001-06-12
JP2003515551A (ja) 2003-05-07
ITMI20002556A1 (it) 2002-05-28
FR2801506B1 (fr) 2002-12-27
CA2389349A1 (en) 2001-06-07
NO20021963D0 (no) 2002-04-25
IL149362A0 (en) 2002-11-10
SK7432002A3 (en) 2002-10-08
EP2011484A2 (en) 2009-01-07
HUP0203728A2 (hu) 2003-03-28
WO2001039745A2 (en) 2001-06-07
ZA200204147B (en) 2003-01-29
NZ518873A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
PY0111577A (es) Métodos y composiciones para el tratamiento del virus de la hepatitis c
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
NO179893C (no) Anvendelse av et ikke-steroidisk anti-inflammatorisk medikament for fremstilling av et legemiddel
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
ECSP034620A (es) Mezclas o compuestos organicos para el tratamiento de enfermedades de las vias respiratorias
ATE330585T2 (de) Behandlung von atemerkrankungen
FI914460A0 (fi) Aerosolbaerare.
DK0771189T3 (da) Inhalationspræparat
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
JP2006514116A5 (es)
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
BR0012444A (pt) Composições de pó seco
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
PE11399A1 (es) Combinacion de loratadina y un descongestionante para el tratamiento del asma
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
BR0311747A (pt) Composição farmacêutica, forma de dose simples ou de múltiplas doses da composição, kit, e, método para tratar doença
DE69918961D1 (de) Verbesserte inhalationspräparate

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2178943B1

Country of ref document: ES

PC2A Transfer of patent

Owner name: SANDOZ AG

Effective date: 20140514

FD2A Announcement of lapse in spain

Effective date: 20210309